Sat, 25-Jun-2022
Friday 22 Nov 2019 , 3:10 pm

Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek Prostate Cancer Study

Cchek is an early cancer detection technology and its goal is to utilize the technology to determine a patient's cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure.
By SIN Bureau
Share at:

Anixa Biosciences, Inc. announced a collaboration with Urology Centers of Alabama (UCA) in the Cchek early prostate cancer detection study.  UCA will provide patient samples in Anixa's ongoing study, including support of clinical validation of Anixa's Cchek Prostate Cancer Confirmation test. 

UCA is one of several sites across the U.S. participating in this study.  Dr. Charles Edward Bugg, Jr. will serve as the Principal Investigator at UCA.

Amit Kumar, Ph.D., Chief Executive Officer of Anixa, stated, "We are pleased to have another highly regarded urology practice join our team of collaboration partners.  We look forward to UCA's participation as we continue the clinical validation phase of the Cchek Prostate Cancer Confirmation test in preparation for commercial launch later this year."




Neha Mule

Neha writes articles on sectors including medicine, food, materials, and science & technology. A qualified statistician, she has the ability to observe and analyze the trends in global markets and write compelling articles that help CXOs in decision making. She is a bookworm and loves to read fiction, lifestyle, science and technology. Neha comes with 6 years of experience in content writing and editing that involves blog writing, preparation of study materials and OERs.

More from Neha Mule

Related News